Value AD
CAN BE
ALTERNATIVE
INVESTMENT
Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Older Adults (UG3/UH3 Clinical Trial Required)
RFA-AG-25-004
National Institutes of Health
Funding Opportunity Number: RFA-AG-25-004
Opportunity Category: Discretionary
CFDA Number(s): 93.213 -- Research and Training in Complementary and Integrative Health,93.866 -- Aging Research
Cost Sharing or Matching Requirement: No
Posted Date: Apr 24, 2024 12:00:00 AM EDT
Closing Date: Oct 10, 2024 12:00:00 AM EDT
Award Ceiling: none
Award Floor: none
Eligible Applicants: Small businesses,Public housing authorities/Indian housing authorities,Private institutions of higher education,City or township governments,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,County governments,Public and State controlled institutions of higher education,State governments,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Native American tribal organizations (other than Federally recognized tribal governments),Independent school districts,Native American tribal governments (Federally recognized),For profit organizations other than small businesses,Others (see text field entitled "Additional Information on Eligibility" for clarification),Special district governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Agency Name: National Institutes of Health
Description: The purpose of this funding opportunity is to support a multi-center consortium that will function as a clinical trials network to collect safety and early efficacy data in defined groups of older adults with specific chronic pain conditions. This funding opportunity will use a UG3/UH3 phased innovation mechanism, and responsive applications must include a research plan describing both UG3 and UH3 phases. UG3 (1st phase) studies, lasting up to 2 years, should involve preliminary studies in healthy older adults across a broad age range to evaluate safety, pharmacokinetic, and pharmacodynamic properties of psychedelic agents and preliminary testing of study elements that will inform further development and testing in the UH3 (2nd) phase. UH3 studies, lasting up to 3 years, should include expanded safety and preliminary efficacy studies in older adults with chronic pain conditions and include participants with non-contraindicated co-occurring conditions representative of real-world older adults. In both phases of the award, participants across a broad range of ages should be included, with particular attention to strata at the upper age range (i.e., 75-80 years, and 80+ years old). For the purposes of this RFA, the term psychedelic includes classic psychedelics, typically understood to be 5-HT2 agonists such as psilocybin,N,N-Dimethyltryptamine(DMT), lysergic acid diethylamide (LSD), and mescaline, as well as entactogens or empathogens such as methylenedioxymethamphetamine (MDMA). Synthetic analogs of these agents are also included. Cannabis, ketamine, and their related products are not considered psychedelic agents in this RFA.
Grantor Contact Information: NIH Grants Information grantsinfo@nih.gov
